Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
NCT ID: NCT01943045
Last Updated: 2015-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
81 participants
INTERVENTIONAL
2013-09-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NGM282 Dose 1
NGM Dose 1
NGM282
NGM282 Dose 2
NGM Dose 2
NGM282
NGM282 Dose 3
NGM Dose 3
NGM282
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGM282
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI range of 24-40 kg/m2, inclusive
* No active coronary artery disease
* Resting heart rate in the range of 40-100 bpm
Exclusion Criteria
* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NGM Biopharmaceuticals Australia Pty Ltd
INDUSTRY
NGM Biopharmaceuticals, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex M DePaoli, MD
Role: STUDY_DIRECTOR
NGM Biopharmaceuticals, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NGM Clinical Study Site 6103
Melbourne, Victoria, Australia
NGM Clinical Study Site 6104
Melbourne, Victoria, Australia
NGM Clinical Study Site 6101
Perth, Western Australia, Australia
NGM Clinical Study Site 6403
Auckland, , New Zealand
NGM Clinical Study Site 6405
Auckland, , New Zealand
NGM Clinical Study Site 6401
Christchurch, , New Zealand
NGM Clinical Study Site 6406
Dunedin, , New Zealand
NGM Clinical Study Site 6404
Tauranga, , New Zealand
NGM Clinical Study Site 6402
Wellington, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
DePaoli AM, Zhou M, Kaplan DD, Hunt SC, Adams TD, Learned RM, Tian H, Ling L. FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis. Diabetes. 2019 Jun;68(6):1315-1328. doi: 10.2337/db18-1305. Epub 2019 Mar 12.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-0102
Identifier Type: -
Identifier Source: org_study_id